Information Provided By: 
Fly News Breaks for July 12, 2017
INCY
Jul 12, 2017 | 07:27 EDT
Oppenheimer analyst Jay Olson says Incyte's shares could see a 9% increment in value if the July 25 pipeline update on Olumiant is favorable pointing to a resubmission post-CRL without any new clinical trials required. Separately, Incyte's valuation could reduce by around 11% in the analyst's worst case scenario if read across from MYSTIC is negative based on a positive result for the PD-L1 plus CTLA-4 combo versus chemo in 1L NSCLC all comers.
News For INCY From the Last 2 Days
INCY
Apr 25, 2024 | 09:27 EDT
